New medication sinus thrombosis just as safe but more patient-friendly

Amsterdam UMC led trial included centres from 5 continents and found no decrease in effectivity or safety

2025-02-20

(Press-News.org) Patients affected by sinus thrombosis are treated with blood thinners. Traditionally, these patients are prescribed vitamin K antagonists (VKAs). In order to give the correct dosage, regular check-ups at the thrombosis service are necessary. A global study, coordinated by Amsterdam UMC, now shows that new medication, direct oral anticoagulants (DOACs), are equally safe and effective. The study was published today in The Lancet Neurology.

A big advantage is that this medication is more user-friendly because regular thrombosis monitoring is no longer necessary. Neurologist and research leader Jonathan Coutinho: "We think these new drugs will give patients a lot of ease of use. We also expect that it will lead to changes in the international standards for the treatment of these patients and that DOACs will probably become the standard for these patients in the future."

Sinus thrombosis is a rare and serious form of stroke that mainly affects people under the age of 50, with about 300 cases in the Netherlands every year, three quarters of which are women. This condition causes a blockage in the blood vessels of the brain, which can lead to serious complications such as brain hemorrhages. The most common symptoms are excruciating headaches, paralysis symptoms and seizures.

Effectiveness and safety
In this largest international study of sinus thrombosis over the past 25 years, researchers from Amsterdam UMC compared the existing treatment with vitamin K antagonists (VKAs) with the new treatment with oral anticoagulants (DOACs). In total, data was collected from 619 patients from 23 countries across 5 continents. Of these 619 patients, 65% were treated with a DOAC and 35% with a VKA.

To assess the safety of the treatment, the researchers looked at the occurrence of major bleeding. This is the main side effect of blood thinners. Within six months of the diagnosis of sinus thrombosis, 3% of patients in both the DOAC and VKA groups experienced a new thrombosis or major bleeding. There is therefore no difference in effectiveness and safety between DOACs and VKAs.

"We are very happy that we were able to carry out this major study with our extensive international network. Especially after the introduction of the GDPR, these kinds of studies are very difficult to carry out in practice, but thanks to joint forces we succeeded," concludes Coutinho.

END

ELSE PRESS RELEASES FROM THIS DATE:

About 740,000 global deaths from suicide occur annually--that's one death every 43 seconds

2025-02-20

Every minute, four males and six females need inpatient treatment due to suicide attempts around the world. Males die from suicide at twice the rate of females, and their attempts result in death three times more often than female attempts. Globally, 10% of suicides by males and 3% by females were with guns. In the U.S., 55% by males and 31% by females were with guns. Between 1990 and 2021, the global age-standardized death rate for suicide declined by almost 40%, indicating that intervention and prevention are ...

Experts strongly recommend against spine injections for chronic back pain

2025-02-20

Spine injections should not be given to adults with chronic back pain because they provide little or no pain relief compared with sham injections, say a panel of international experts in The BMJ today. Their strong recommendations apply to procedures such as epidural steroid injections and nerve blocks for people living with chronic back pain (lasting at least 3 months) that is not associated with cancer, infection or inflammatory arthritis. Their advice is based on the latest evidence and is part of The BMJ’s ‘Rapid ...

Racism in medicine - are things getting better?

2025-02-20

Five years on since The BMJ’s special issue on racism in medicine, and a global pandemic, the landscape is very different, but has racism in the NHS and UK medicine got better or worse? In 2020, a BMJ investigation found that UK medical schools were failing to deal with complaints of racism. Another round of requests to the UK’s 46 medical schools has now found that eight in 10 (34 of 41 that responded) are collecting data on complaints about racism, up from half in 2020. And the number ...

Forcing UK creatives to ‘opt out’ of AI training risks stifling new talent

2025-02-20

The UK government should resist allowing AI companies to scrape all copyrighted works unless the holder has actively “opted out”, as it puts an unfair burden on up-and-coming creative talents who lack the skills and resources to meet legal requirements. This is according to a new report from University of Cambridge experts in economics, policy and machine learning, who also argue the UK government should clearly state that only a human author can hold copyright – even when AI has been heavily involved. A collaboration between three Cambridge initiatives – ...

Almost 90% of people would agree to genetic testing to tailor medication use, survey finds

2025-02-20

New research shows almost 90% of people in England would agree to genetic testing to get the most effective medication and reduce the risk of side effects 85% thought that the NHS should offer pharmacogenomic testing to people with multiple health conditions 58% of people thought that the NHS should offer this testing to everyone 91% wanted access to their own pharmacogenomic data, with many wanting this via the NHS app Pharmacogenomics – an individual’s genetic response to medications – is an increasingly important strand of personalised healthcare but little is known about the public's views ...

Study: UTA research drives widespread economic impact

2025-02-19

University of Texas at Arlington research projects contributed $59 million to the national economy in 2024—an increase of 39% from 2023, according to a new report from the Institute for Research on Innovation and Science (IRIS). UTA has invested heavily in research infrastructure, purchasing cutting-edge scientific equipment and technology, such as North Texas’ most advanced gene sequencer and a super-sensitive magnetic resonance imaging machine for the Clinical Imaging Research Center. The funds also support collaboration with other research organizations. UTA worked through 1,144 unique ...

Promising results from first prenatal therapy for spinal muscular atrophy

2025-02-19

(MEMPHIS, Tenn. – February 19, 2025) Spinal muscular atrophy (SMA) is a progressive neurodegenerative disorder set in motion before birth. Scientists at St. Jude Children’s Research Hospital led the first in uterotreatment of SMA with the orally administered drug risdiplam. More than two years after the child was born, no identifiable features of SMA have been observed. This study demonstrates the feasibility of treating SMA prenatally and supports further investigation into the approach. The findings were published ...

Nitrogen fixation on marine particles is important in the global ocean

2025-02-19

How on Earth? It has puzzled scientists for years whether and how bacteria, that live from dissolved organic matter in marine waters, can carry out N2 fixation. It was assumed that the high levels of oxygen combined with the low amount of dissolved organic matter in the marine water column would prevent the anaerobic and energy consuming N2 fixation. Already in the 1980s it was suggested that aggregates, so-called “marine snow particles”, could possibly be suitable sites for N2fixation, ...

FDA approves vimseltinib for tenosynovial giant cell tumor (TGCT)

2025-02-19

The U.S. Food and Drug Administration (FDA) has approved vimseltinib (RomvimzaTM) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the tissue that lines the joints. Sarcoma oncologist William Tap, MD, Chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center (MSK), led the international phase 3 MOTION trial that resulted in the drug’s approval. Vimseltinib is a type of targeted therapy called a kinase inhibitor and is taken as a pill. “This approval is an exciting advance for ...

Columbia Climate School launches M.S. in Climate Finance

2025-02-19

The Columbia Climate School has announced the first master’s degree program in the United States for climate finance. In close collaboration with the Columbia Business School, this interdisciplinary degree will drive impactful solutions to the climate crisis through advanced financial tools and scientific knowledge. This is the third master’s program announced by the Climate School, in addition to an M.A. in Climate and Society and an M.S. in Climate degree. “The world needs problem-solvers to address the global climate crisis,” said Alexis Abramson, dean of the Columbia Climate School. “Everyone ...

New medication sinus thrombosis just as safe but more patient-friendly

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: